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Background: In the recent years numerous studies have analysed the effects of neurotrophins
on allergic inflammation in airway diseases reporting increased neurotrophin levels locally in
the airways as well as in serum of asthmatic patients. We aimed to investigate if levels of neu-
rotrophins in serum of asthmatic children are influenced by the genotype of functional variants
within genes encoding analysed neurotrophins and their specific receptors.
Methods: In the study we included 98 children diagnosed with asthma. Genotyping of 9 poly-
morphisms located in neurotrophins genes and their receptors genes was done with use of Taq-
Man SNP genotyping assays or PCR-RFLP. The serum levels of four neurotrophins (BDNF, NGF,
NTF3, NTF4) were analysed during exacerbation of asthma symptoms with use of DuoSet ELISA
Development Kit (R&D).
Results: The two patients with the genetic variant A/A of NTRK1 (rs6334) showed significantly
higher NGF serum concentrations (113.4 and 218.1 pg/mL) as compared to the mean NGF
serum concentrations in the total group of patients (34.8 pg/mL). We also observed a signifi-
cant epistatic interactions between variants of NGF rs6330 and NTRK1 rs6334 that influenced
NGF serum level (P Z 0.0004). Analysis of four neurotrophins serum levels in relation to
different genotypes of analysed neurotrophins genes showed no significant differences among
analysed asthmatic children.f Molecular and Cell Biology, Department of Pediatric Pulmonology, Allergy and Clinical Immunology,
, 27/33 Szpitalna St., 60-572 Poznan, Poland. Tel.: þ48 061 8491311; fax: þ48 061 8480111.
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NTRK1 and NGF genes influence NGF level 31Conclusions: Our results suggest that, among analysed neurotrophins, NGF serum levels may be
influenced by the genotype of NTRK1 gene individually as well as in the interaction with NGF
functional genetic variant suggesting their involvement in allergic inflammation in asthma.
Serum levels of the other neurotrophins do not seem to be affected by the variants in the ana-
lysed genes.
ª 2012 Elsevier Ltd. All rights reserved.Introduction
Neurotrophins are neurotrophic growth factors that stimu-
late neurodevelopment in the nervous system. They are
also mediators of the interactions between immune and
neuronal cells, integrating the neuroimmune crosstalk in
the pathogenesis of allergic diseases including asthma.
Apart from neurons, neurotrophins are potent to activate
also structural (airway epithelium) and immune cells
(eosinophils, lymphocytes, mast cells). It was reported that
structural and inflammatory cells express neuronal recep-
tors and release mediators which directly communicate
with nerve endings in the airways and skin.1 It has been also
observed that allergic asthma is associated with changes in
neuronal control in the airways.2 This, in turn, may modu-
late allergen sensitization and allergic inflammation.3
Neurotrophins are polypeptides that support growth,
differentiation, and survival of neurons in developing and
adult nervous systems. The prototypical neurotrophin is
nerve growth factor (NGF) and this family also includes
brain-derived neurotrophic factor (BDNF), neurotrophin 3
and neurotrophin 4. Neurotrophins act via a family of
receptor tyrosine kinases first identified as tropomyosin-
related kinases (Trks) initiating cell proliferation and
survival. NGF preferentially activates TrkA receptors, BDNF
and NTF3 are selective for TrkB receptors, and NTF4 is
selective for TrkC receptors. Neurotrophins also act via an
additional receptor (p75NTR), which has no tyrosine kinase
activity and, unlike Trk receptors, binds neurotrophins with
low affinity and specificity,4 however effectively binds pro-
neurotrophins inducing cell death.5
In the recent years numerous studies have analysed the
effects of neurotrophins on allergic inflammation in airway
diseases. Elevated BDNF, NGF and NTF3 levels have been
found in bronchoalveolar lavage fluid (BALF) after allergen
challenge in allergic asthmatic patients.2,6 Asthmatic
patients demonstrated elevated levels of neurotrophins
(NGF and BDNF) in serum and locally in the airways7e9 and
significant increase in neurotrophins levels in the airways
was observed following allergen provocation.6,10 Increased
neurotrophins concentration (BDNF) also correlated with
clinical parameters of allergic airway dysfunction such as
airflow limitation and airway hyperresponsiveness in asth-
matic patients,11 whereas its level normalized after anti-
inflammatory treatment with inhaled corticosteroids.9 All
neurotrophins analysed in this study were also found to
upregulate the neurotrophin receptors on eosinophils from
BALF following allergen challenge in asthmatic patients,
resulting in increased viability of eosinophils in vitro after
incubation with all four neurotrophins.12 These results
indicated that neurotrophin mediated activation ofbronchial eosinophils might play a role in the regulation of
eosinophilic inflammation in allergic asthma.
Based on the previous studies indicating that functional
polymorphisms within neurotrophins and their receptors
genes may alter gene expression and protein secretion, we
hypothesized that neurotrophins protein levels are affected
by functional polymorphisms within neurotrophins genes
and their receptors altering circulating neurotrophin
concentrations in asthma. Therefore, in the present study
we aimed to investigate the correlation between functional
variants of four neurotrophin genes and their specific
receptors genes and the serum levels in asthmatic children
during symptoms exacerbation.
Methods
Study design
Children diagnosed with asthma were included in this study.
The neurotrophins levels were analysed during exacerba-
tion of symptoms in the course of disease. Exacerbation
was defined as presence of asthma symptoms (daytime
symptoms, nocturnal symptoms, limitation of daily activi-
ties, the need for reliever treatment, reduced lung func-
tion). All participants as well as their parents have given
written informed consent. Local ethics committee
accepted the project. Study was performed in compliance
with the Code of Ethics of the World Medical Association
(Declaration of Helsinki).
Patients
The study was performed on Polish sample of 98 asthmatic
patients of Caucasian origin in age from 6 to 18 years old.
Patients were recruited from inpatients treated in the
Department of Pediatric Pulmonology, Allergy and Clinical
Immunology of Poznan University of Medical Sciences and
from the Outpatient Clinic of Allergology in Rzeszow.
Asthma diagnosis was made according to GINA recommen-
dation, based on clinical asthma symptoms and lung func-
tion test. Spirometry was performed on Lung Test 1000
(MES) according to ERS/ATS guidelines.13
Asthma severity was based on GINA guidelines into mild,
moderate and severe at least 6 months before inclusion in
the study.14
Allergic predisposition was suggested by current or past
symptoms of atopic dermatitis, allergic rhinoconjunctivitis
(seasonal or perennial) or food allergy. Atopy was
confirmed when children fulfilled the following criteria:
total IgE level higher than the upper normal limits for age;
32 A. Szczepankiewicz et al.positive skin prick test to at least one aero-allergen (Der-
matophagoides pteronyssinus, Dermatophagoides farinae,
cat, dog, Alternaria alternata, Cladosporium herbarum;
pollen: grass mix, rye, birch pollen, alder, hazel e Aller-
gopharma, Germany). Any reaction with mean wheal
diameter at least 3 mm greater than negative control was
regarded positive. Total serum IgE level was measured by
a fluoroimmunossay with Pharmacia UniCap 100 System
(Pharmacia, Uppsala, Sweden) following manufacturer’s
instruction.Genotyping
We have genotyped 9 SNPs from 7 genes involved in neu-
rotrophic signalling cascade and encoding neurotrophins
(BDNF, NGF, NTF-3, NTF-4) and their specific receptors
(NTRK1, NTKR2, NTRK3). The SNP selection was based on at
least two of the following criteria: functionality confirmed
in previous experimental studies, high frequency
(MAF > 0.15), indication as tagSNP in HapMap Caucasian
database (www.hapmap.org/) or previously reported
papers with serum protein level (both positive and negative
findings). The chosen SNPs cover both coding regions as well
as non-coding regions (promoters, introns, UTRs). The list
of polymorphisms included in this study was presented in
Table 1.
The DNA was extracted from 10 ml of EDTA anti-
coagulated whole blood using the salting out method Miller
1988.15 Genotyping of 9 polymorphisms was done with use
of PCR-RFLP or TaqMan SNP genotyping assays (Applied
Biosystems). The sequences of the primers and conditions
for the variants analysed with PCR-RFLP method and the
assays ID numbers for polymorphisms analysed with use of
50nuclease method (TaqMan assays) were shown in Table 1.
The amplification of DNA samples with use of TaqMan SNP
genotyping assay plates was done in ABI Prism 7900HT
Sequence Detection System. Data acquisition and analysis
was performed using the allelic discrimination analysis
module in SDS v2.1 software (Applied Biosystems). Reaction
components and amplification parameters were based on
manufacturer’s instructions.
For each reaction plate genomic control DNA samples
and non-template controls (water) were included. The
control of RFLP analysis and TaqMan SNP genotyping assay
was also performed (25% of randomly chosen samples fromTable 1 Description of candidate gene polymorphisms included
Gene SNP Location in the gene MAF (Cau
BDNF rs6265 Val74Met, exon 1 0.19
NGF rs6330 Ala35Val, exon 3 0.40
Rs11102930 Promoter region 0.27
NTF3 Rs1805149 Glu89Gly, exon 1 0.14
Rs6332 Pro84Pro, exon 1 0.45
NTF4 Rs11669977 Promoter region 0.20
NTRK1 Rs6334 Gln558Gln, exon 4 0.22
NTRK2 Rs1212171 Promoter region 0.40
NTRK3 Rs11073763 Intron 12, tagSNP 0.43both groups for each SNP) to check for genotyping accuracy
and identical genotypes were identified in all repeated
samples. The genotyping was performed without knowing
the clinical status of the subjects.
Analysis of neurotrophins concentration
Blood samples for serum were taken for tubes without
anticoagulant between 10 and 12 a.m. and kept at room
temperature for 1 h. After that, blood was centrifuged to
obtain serum and samples were immediately frozen at
80 C for further analysis. Concentrations of neuro-
trophins was measured using DuoSet ELISA Development Kit
(R&D). For BDNF serum samples were diluted 1:100 in
Reagent Diluent (1% BSA in PBS), for other neurotrophins,
due to low serum levels, undiluted samples were used. The
absorbance was read on a plate reader at 450 nm wave-
length (Asys UVM 340). Neurotrophin concentration was
quantified against a standard curve calibrated with known
amounts of protein. Assays were run in duplicates and
intrassay variability coefficient was assessed to be below
5%.
Statistical analysis
Differences in neurotrophins levels between patients with
different genotypes were analysed with use of ANOVA test.
P value lower than 0.05 was considered significant. All
significance levels were two-tailed. To investigate if neu-
rotrophin levels are influenced by the genotype of both
neurotrophin gene and neurotrophin receptor gene, we
performed two-way ANCOVA analysis with neurotrophin
levels as dependent variables and genotypes of appro-
priate polymorphisms as independent predictors. Calcula-
tions were performed using the Statistica version 9.0
software.Results
Subjects characteristics
Ninety eight asthmatic children were included into the
study. The demographic characteristics and clinical
description of the studied population was given in Table 2.in this study.
casian) Genotyping method Enzyme/TaqMan assay
RFLP Eco72I
TaqMan C__2525309_10
TaqMan C__26680904_10
RFLP HaeIII
TaqMan C__170592_10
TaqMan C__2884550_10
RFLP TaiI
TaqMan C__7424025_10
TaqMan C__3041241_10
Table 2 Characteristics of the asthmatic patients.
Patients group
Gender, male, N (%) 81 (82.6%)
Age, years (mean  SD) 11.1  3.8
Asthma severity
Mild, N (%) 19 (19.4)
Moderate, N (%) 55 (56.1)
Severe, N (%) 24 (24.5)
Positive SPT (%) 73.2
GC inhaled treatment (%) 97.6
LABA treatment (%) 66.7
Antileukotrienes treatment (%) 45.3
FEV1% pred exacerbation (mean  SD) 81.6  14.44
FEV1% pred asymptomatic (mean  SD) 103.8  87.7
FEV1/FVC pred exacerbation (mean  SD) 85.8  14.5
FEV1/FVC pred asymptomatic (mean  SD) 96.4  12.5
exNO (ppb) (mean  SD) 33  43.4
IgE (IU/mL) (mean  SD) 303.1  411.5
NTRK1 and NGF genes influence NGF level 33Asthmatic boys were more prevalent in our group of
patients (82.6% of the patients’ group).
Analysis of neurotrophin serum levels and
neurotrophin gene variants
First, we examined the hypothesis that serum neurotrophin
levels are influenced by functional polymorphisms localized
within the four neurotrophin genes (BDNF, NGF, NTF3,
NTF4). We found that none of the variants analysed in the
present study affected significantly serum level of the
appropriate protein (rs6265 variant for BDNF; rs6330 and
rs11102930 for NGF; rs6332 and rs1805149 for NTF3 and
rs11669977 for NTF4) (Table 3). We observed that patients
with Met/Met genotype of rs6265 BDNF gene polymorphism
demonstrated lower BDNF serum levels in comparison to
patients with other BDNF genotypes and that patients
carrying GG genotype of rs6332 NTF3 gene presented higher
NTF3 serum levels, however those differences were not
statistically significant.
Analysis of neurotrophin serum levels and
neurotrophin receptors gene variants
Next, we investigated if polymorphic variants located
within the genes encoding specific neurotrophin receptors
may influence the serum level of unbound/active protein.
We found that in two patients with AA genotype of NTRK1
rs6334 variant was associated with significantly higher NGF
serum level (Table 3). The other analysed variants of
receptors genes in relation to neurotrophin serum levels did
not differed significantly between patients with different
genotypes (Table 3).
Analysis of epistatic effects of neurotrophins and
neurotrophins receptors variants on serum level
Finally, we tested the interactive effects of the genetic
variants in four neurotrophins and polymorphisms in thecorresponding specific receptors on neurotrophins serum
level in asthmatic children. We observed a significant
epistatic interactions between NGF rs6330 variant and
NTRK1 rs6334 polymorphism that influenced NGF serum
level (F Z 6.715, P Z 0.0004) (Fig. 1).Discussion
This is the first study analysing a relationship between
neurotrophins serum levels (BDNF, NGF, NT-3 and NT-4) and
genotypes of the variants within neurotrophins genes and
their receptors genes (NTRK1 encoding the high-affinity
NGF receptor TrkA; NTRK2 encoding the high-affinity
BDNF and NT-4 receptor TrkB; and NTRK3 encoding the
high-affinity NT-3 receptor TrkC) that are possibly involved
in the gene expression and protein secretion. The main
finding of this study is a plausible impact of NTRK1 rs6334
genotype and interaction between variants of NGF rs6330
and NTRK1 rs6334 on NGF serum level in asthmatic patients.
The most extensively studied neurotrophin in regard to
asthma was BDNF. It was found that serum BDNF level was
increased in adult patients with asthma9,11 and its level was
normalized after glucocorticoid treatment.9 However, this
finding was not confirmed by the other study.16 Recently,
the first paper in a paediatric population of asthmatic
patients was published, where the authors observed that
BDNF plasma levels were significantly higher in paediatric
patients with moderate and severe asthma in comparison to
controls and mild asthmatic patients.17 The studies
reporting the association of the other neurotrophins levels
with asthma are less abundant. In respect to NGF, a study
by Bonini et al.7 demonstrated increased serum NGF level in
patients with allergic asthma as compared to healthy
controls. The other studies reporting on serum levels of
neurotrophins in asthma included analysis by Noga et al.9
where the authors investigated three neurotrophins
(BDNF, NGF and NTF3) in allergic asthmatic patients treated
and untreated with inhaled steroids and control subjects.
They reported that BDNF and NGF levels were significantly
higher in untreated patients with allergic asthma as
compared to healthy controls and asthmatic patients
treated with inhaled corticosteroids, whereas the highest
level of NTF3 was observed in the asthmatic patients
treated with ICS. The more recent study performed by
Koskela et al.18 in relation to chronic cough reported that
NGF level in both serum and sputum was significantly
increased in a subgroup of patients with asthma, whereas
BDNF showed no difference between the analysed groups.
In our previous study,19 we analysed the serum levels of
four neurotrophins (BDNF, NGF, NTF3, NTF4) in the same
group of asthmatic children and we found that NTF3 and
NTF4 levels were associated with asthma severity.
In respect to analysis of possible influence of genotypes
of functional variants on neurotrophin levels, there are to
date only few reports. The previous studies in this regard
analysed BDNF level in relation to BDNF rs6265 variant that
results in abnormal cellular trafficking and packaging of
pro-BDNF leading to reduced secretion of mature BDNF
protein in case of Met allele.20 The influence of this variant
on BDNF serum or plasma level was confirmed in Met allele
carriers as they had lower BDNF serum levels in comparison
Table 3 Analysis of serum neurotrophin levels stratified by genotype of neurotrophins and neurotrophin receptors genes
variants (* indicates significance).
Gene SNP ID Genotype N Mean SD F P
BDNF serum level (pg/mL)
BDNF Rs6265 Met/Met 5 28,073.22 10,601.95 1.144 0.323
Met/Val 37 41,082.74 23,260.50
Val/Val 43 36,964.22 16,763.81
NTRK2 Rs1212171 T/T 25 31,022.61 12,585.33 0.976 0.382
C/T 34 36,258.55 17,622.30
C/C 8 37,999.26 18,950.99
NGF serum level (pg/mL)
NGF Rs6330 A/A 9 32.80 69.06 0.300 0.742
A/G 22 22.57 47.91
G/G 14 16.91 28.81
Rs11102930 A/A 27 23.09 56.85 0.210 0.810
A/G 25 22.46 33.32
G/G 7 11.18 9.91
NTRK1 Rs6334 G/G 23 31.50 52.30 5.993 0.005*
G/A 14 46.97 51.50
A/A 2 113.44
218.13
e
NT3 serum level (pg/mL)
NTF3 Rs6332 G/G 16 298.40 386.97 1.376 0.259
G/A 34 163.18 323.33
A/A 20 129.40 252.47
Rs1805149 A/A 2 21.73 e 0.399 0.671
A/G 1 48.38 0.00
G/G 78 195.14 315.66
NTRK3 Rs11073763 A/A 14 118.44 298.21 0.448 0.640
A/G 33 210.56 346.04
G/G 40 180.30 270.08
NT4 serum level (pg/mL)
NTF4 Rs11669977 A/A 71 52.63 88.66 0.184 0.831
A/G 25 66.33 121.01
G/G 4 48.08 39.78
NTRK2 Rs1212171 T/T 38 68.68 107.13 1.714 0.185
C/T 40 36.04 50.80
C/C 14 81.14 145.78
34 A. Szczepankiewicz et al.to carriers of Val allele,21 and the same trend was observed
in our study (carriers of Met/Met genotype had lower BDNF
serum levels than carriers of other genotypes, but this
difference was not significant). BDNF protein level reduc-
tion in Met carriers (Met/Met or Val/Met) in a peripheral
system (amniotic fluid) was also confirmed by Cattaneo
et al.22 However, other studies did not confirm that
observation.23e25 So far, the other neurotrophins levels
have not been analysed in regard to serum level.
Our main observation that NGF serum level may be
influenced by variation in NTRK1 gene as well as by the
interaction between this variant and NGF rs6330 poly-
morphism which indicate that this signalling pathway may
be one of the determinants of NGF protein level. The bio-
logical relevance of rs6334 polymorphism in NTRK1 gene
may be explained by the fact that this silent substitution
(Q558Q) is located in tyrosine kinase domain and neigh-
bouring mutations (G516R and G571R) in this region lead to
diminished NGF-stimulated autophosphorylation of the
receptor26 suggesting the possible role in the alteredintracellular signalling in response to NGF stimulation.27 In
regard to rs6330 variant in NGF gene, this substitution
results in alanine to valine change and is located in the pro-
NGF sequence possibly affecting trafficking of the protein.
The increase in amino acid size (Val) could modify the
tertiary structure of pro-NGF, leading to altered interaction
and signalling via the p75 neurotrophin receptor, as C allele
(corresponding to Ala) was suggested to enhance interac-
tion with the p75 neurotrophin receptor that mediate cell
death.28 We observed that the T allele was associated with
increased NGF serum level, and that increase could be
explained by diminished interaction with p75 receptor and
therefore, impaired intracellular signalling.
This study for the first time presents the comprehensive
analysis of neurotrophins levels in relation to genotypes of
functional variants of neurotrophins genes and their
receptors. However, this report has several limitations such
as relatively small sample size and also a detection limit for
NGF in serum, as it is on relatively low level, so in some
children we were not able to detect it with ELISA method or
Figure 1 The interaction between rs6330 of NGF gene and rs6334 of NTRK1 gene significantly influences NGF serum level in
asthmatic patients (F Z 6.715, P Z 0.0004; vertical lines are 0.95 confidence intervals).
NTRK1 and NGF genes influence NGF level 35its level was below the detection limit of the method (8 pg/
mL), therefore those measurements were excluded from
further analysis. However, positive association between NGF
serum level and rs6334 polymorphism remained significant
when we analysed all samples, including those with unde-
tectable serum NGF. Another limitation of this paper is the
cause of asthmaexacerbatione in about 80% of patients itwas
due to allergen exposure, however in the remaining patients
20% exacerbations were triggered by acute respiratory infec-
tion which could also influence our results (at least for BDNF)
based on the previous report showing that acute bacterial
infectionmayaffectBDNF level.29Amongother limitations,we
should also mention the fact that neurotrophin serum levels
could be influenced by combined treatment with inhaled
steroids and LABA present in 66.7% of patients, as such
combination was reported previously to influence BDNF
level.30 However, our prioritywas to adjust the best treatment
schedule for the paediatric patients with asthma.
In conclusion, we found that NTRK1 variant (rs6334) and
epistatic interaction between NGF and NTRK1 variants are
possibly influencing NGF serum level in asthmatic patients.
The other genetic variants in neurotrophins genes and their
receptors do not affect neurotrophins serum levels in the
analysedpopulation. However, our preliminary study involved
a limited number of patients and further studies are necessary
to confirm our observations and draw definite conclusions.
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